口服轮状病毒疫苗Rotarix保护效果的Meta分析

魏宇航 李金松 孙晓曼 庞立丽 王宏 章青 王萌璇 毛彤瑶 王明雯 范佳欣 李丹地 吴建军

魏宇航, 李金松, 孙晓曼, 庞立丽, 王宏, 章青, 王萌璇, 毛彤瑶, 王明雯, 范佳欣, 李丹地, 吴建军. 口服轮状病毒疫苗Rotarix保护效果的Meta分析[J]. 疾病监测, 2021, 36(8): 797-805. doi: 10.3784/jbjc.202106090328
引用本文: 魏宇航, 李金松, 孙晓曼, 庞立丽, 王宏, 章青, 王萌璇, 毛彤瑶, 王明雯, 范佳欣, 李丹地, 吴建军. 口服轮状病毒疫苗Rotarix保护效果的Meta分析[J]. 疾病监测, 2021, 36(8): 797-805. doi: 10.3784/jbjc.202106090328
Wei Yuhang, Li Jinsong, Sun Xiaoman, Pang Lili, Wang Hong, Zhang Qing, Wang Mengxuan, Mao Tongyao, Wang Mingwen, Fan Jiaxin, Li Dandi, Wu Jianjun. Meta analysis on protection effect of Rotarix oral rotavirus vaccine[J]. Disease Surveillance, 2021, 36(8): 797-805. doi: 10.3784/jbjc.202106090328
Citation: Wei Yuhang, Li Jinsong, Sun Xiaoman, Pang Lili, Wang Hong, Zhang Qing, Wang Mengxuan, Mao Tongyao, Wang Mingwen, Fan Jiaxin, Li Dandi, Wu Jianjun. Meta analysis on protection effect of Rotarix oral rotavirus vaccine[J]. Disease Surveillance, 2021, 36(8): 797-805. doi: 10.3784/jbjc.202106090328

口服轮状病毒疫苗Rotarix保护效果的Meta分析

doi: 10.3784/jbjc.202106090328
基金项目: 国家重点研发计划(No. 2018YFC1200602);国家科技重大专项(No. 2018ZX10711–001,No.2018ZX10201002);国家自然科学基金(No. 21934005,No. 81601813)
详细信息
    作者简介:

    魏宇航,男,河北省安国市人,在读硕士,就读于甘肃中医药大学公共卫生学院,主要从事轮状病毒相关研究,Email:yuhang960811@163.com

    通讯作者:

    李丹地 Tel:010–58900899,Email:dandili@126.com

    吴建军,Tel:0931–8765521,Email:wjj@gszy.edu.cn

  • 中图分类号: R211; R373.2

Meta analysis on protection effect of Rotarix oral rotavirus vaccine

Funds: This study was supported by the National Key Research and Development Program (No. 2018YFC1200602), National Science and Technology Major Projects (No. 2018ZX10711–001, No. 2018ZX10201002) and National Natural Science Foundation of China (No. 21934005, No. 81601813)
More Information
  • 摘要:   目的   评价口服轮状病毒疫苗Rotarix在全球范围内使用后对轮状病毒胃肠炎(RVGE)的保护效果,为Rotarix疫苗在全球轮状病毒高低死亡率地区的使用提供更好的科学依据。  方法   检索2001 — 2021 年公开发表的符合入选标准的有关Rotarix疫苗的文献,共纳入了63 990人研究对象,其中低死亡率地区纳入研究对象27 725人,高死亡率地区纳入研究对象 36 265人,使用RevMan 5.3软件进行统计分析。  结果   在低死亡率地区,Rotarix对RVGE、SRVGE的保护率为VERVGE=73%(95%CI: 58%~82%)、VESRVGE=89%(95%CI: 80%~94%),其中对黄色人种RVGE、SRVGE保护效果为VERVGE=69%(95%CI: 39%~84%)、VESRVGE=91%(95%CI: 74%~97%),对白色人种RVGE、SRVGE保护效果为VERVGE=78%(95%CI: 73%~83%)、VESRVGE=90%(95%CI: 85%~93%);在高死亡率地区, Rotarix对RVGE、SRVGE的保护率为VERVGE=53%(95%CI: 27%~70%)、VESRVGE=70%(95%CI: 42%~85%),其中对黄色人种RVGE、SRVGE保护效果为VERVGE=61%(95%CI: 45%~73%)、VESRVGE=80%(95%CI: 68%~87%),对黑色人种RVGE、SRVGE保护效果为VERVGE=43%(95%CI: -98%~68%)、VESRVGE=42%(95%CI: 25%~56%)。  结论   在任何地区口服Rotarix对预防任意严重程度轮状病毒胃肠炎都有一定的保护效果,对重症轮状病毒胃肠炎保护效果更好。 在低死亡率地区,Rotarix对白色人种的任何严重程度轮状病毒胃肠炎的保护效果优于黄色人种;在高死亡率地区,Rotarix对黄色人种的任何严重程度轮状病毒胃肠炎的保护效果优于黑色人种。
  • 图  1  文献筛选流程图

    Figure  1.  Flow chart of literature screening

    图  2  Rotarix在低死亡率地区对RVGE保护效果Meta分析森林图

    Figure  2.  Meta analysis on Rotarix's protection effect against RVGE in low-mortality region

    图  3  Rotarix在低死亡率地区对RVGE保护效果亚组分析森林图

    Figure  3.  Subgroup analysis on Rotarix's protection effect against RVGE in low-mortality region

    图  4  Rotarix在低死亡率地区对SRVGE保护效果Meta分析森林图

    Figure  4.  Meta analysis on protection effect of Rotarix against SRVGE in low-mortality region

    图  5  Rotarix在低死亡率地区对SRVGE保护效果亚组分析森林图

    Figure  5.  Subgroup analysis on protection effect of Rotarix against SRVGE in low-mortality region

    图  6  Rotarix在高死亡率地区对RVGE保护效果Meta分析森林图

    Figure  6.  Meta analysis on Rotarix's protection effect against RVGE in high-mortality region

    图  7  Rotarix在高死亡率地区对RVGE保护效果亚组分析森林图

    Figure  7.  Subgroup analysis on Rotarix's protection effect against RVGE in high-mortality region

    图  8  Rotarix在高死亡率地区对SRVGE保护效果Meta分析森林图

    Figure  8.  Meta analysis on protection effect of Rotarix against SRVGE in high-mortality region

    图  9  Rotarix在高死亡率地区对SRVGE保护效果亚组分析森林图

    Figure  9.  Subgroup analysis on protection effect of Rotarix against SRVGE in high-mortality region

    表  1  符合纳入保护效果分析标准文献的基本情况

    Table  1.   Basic information of documents meeting inclusion criteria for protection effect analysis

     第一作者发表年份儿童年龄
    (周)
    轮状病毒胃肠炎发病率a严重轮状病毒胃肠炎发病率a地区
    疫苗组对照组疫苗组对照组
    Ruiz-Palacios420066~1312/900977/8858拉丁美洲
    Perez-Schael520076~1258/139246/45427/139234/454拉丁美洲
    Rojas620078~165/15920/1600/1596/160哥伦比亚(南美洲)
    Nigel A. Cunliffe7201110~14193/1030121/483101/103079/483马拉维(南非)
    S.A. Madhi820126~1441/84348/40811/84313/408南非
    Timo Vesikari920046~1213/24523/1233/24510/123芬兰(欧洲)
    Vesikari1020076~1485/2573204/130224/2572127/1302欧洲
    Kong Boo Phua1120096~172/526351/5256中国(香港、台湾)、新加坡
    Naohisa Kawamura1220116~1414/49834/2502/49812/250日本
    Yu-Lung Lau1320136~121/149423/1499中国香港
    Rong-cheng Li1420147~1670/1575167/157321/157575/1573中国
    Kong Boo Phua15201611~171/323716/3239新加坡
      注:拉丁美洲、哥伦比亚(南美洲)、马拉维(南非)、南非等地区为高死亡率地区;芬兰(欧洲)、欧洲、中国(香港、台湾)、新加坡、日本等地区为低死亡率地区。a. 数据为患病数/总数
    下载: 导出CSV
  • [1] Crawford SE, Ramani S, Tate JE, et al. Rotavirus infection[J]. Nat Rev Dis Primers, 2017, 3: 17083. DOI:  10.1038/nrdp.2017.83.
    [2] 中华预防医学会. 儿童轮状病毒胃肠炎免疫预防专家共识(2020版)[J]. 中华流行病学杂志,2021,42(1):44–57. DOI:10.3760/cma.j.cn112338−20201103−01298.

    Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of childhood rotavirus gastroenteritis (2020 version)[J]. Chin J Epidemiol, 2021, 42(1): 44–57. DOI: 10.3760/cma.j.cn112338−20201103−01298.
    [3] 魏宇航, 王明雯, 毛彤瑶, 等. 口服轮状病毒减毒活疫苗RotaTeq对儿童保护效果和安全性的Meta分析[J]. 国际病毒学杂志,2021,28(2):93–97. DOI:10.3760/cma.j.issn.1673−4092.2021.02.002.

    Wei YH, Wang MW, Mao TY, et al. Meta analysis on effectiveness and safety of a live attenuated oral rotavirus vaccine, RotaTaq among children[J]. Int J Virol, 2021, 28(2): 93–97. DOI: 10.3760/cma.j.issn.1673−4092.2021.02.002.
    [4] Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis[J]. N Engl J Med, 2006, 354(1): 11–22. DOI:  10.1056/NEJMoa052434.
    [5] Perez-Schael I, Salinas B, Tomat M, et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children[J]. J Infect Dis, 2007, 196(4): 537–540. DOI:  10.1086/519687.
    [6] Rojas OL, Caicedo L, Guzmán C, et al. Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine[J]. Viral Immunol, 2007, 20(2): 300–311. DOI:  10.1089/vim.2006.0105.
    [7] Cunliffe NA, Witte D, Ngwira BM, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial[J]. Vaccine, 2012, 30 Suppl 1: A36–A43. DOI:  10.1016/j.vaccine.2011.09.120.
    [8] Madhi SA, Kirsten M, Louw C, et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial[J]. Vaccine, 2012, 30 Suppl 1: A44–A51. DOI:  10.1016/j.vaccine.2011.08.080.
    [9] Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants[J]. Pediatr Infect Dis J, 2004, 23(10): 937–943. DOI:  10.1097/01.inf.0000141722.10130.50.
    [10] Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study[J]. Lancet, 2007, 370(9601): 1757–1763. DOI: 10.1016/S0140−6736(07)61744−9.
    [11] Phua KB, Lim FS, Lau YL, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study[J]. Vaccine, 2009, 27(43): 5936–5941. DOI:  10.1016/j.vaccine.2009.07.098.
    [12] Kawamura N, Tokoeda Y, Oshima M, et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life[J]. Vaccine, 2011, 29(37): 6335–6341. DOI:  10.1016/j.vaccine.2011.05.017.
    [13] Lau YL, Nelson EAS, Poon KH, et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial[J]. Vaccine, 2013, 31(18): 2253–2259. DOI:  10.1016/j.vaccine.2013.03.001.
    [14] Li RC, Huang T, Li YP, et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China[J]. Hum Vaccin Immunother, 2014, 10(1): 11–18. DOI:  10.4161/hv.26319.Epub2013Sep6.
    [15] Phua KB, Lim FS, Quak SH, et al. Efficacy, Immunogenicity and Safety of a Human Rotavirus Vaccine RIX4414 in Singaporean Infants[J]. Ann Acad Med Singap, 2016, 45(2): 44–50.
    [16] Lestari FB, Vongpunsawad S, Wanlapakorn N, et al. Rotavirus infection in children in Southeast Asia 2008-2018: disease burden, genotype distribution, seasonality, and vaccination[J]. J Biomed Sci, 2020, 27(1): 66. DOI: 10.1186/s12929−020−00649−8.
    [17] Sadiq A, Bostan N, Yinda KC, et al. Rotavirus: genetics, pathogenesis and vaccine advances[J]. Rev Med Virol, 2018, 28(6): e2003. DOI:  10.1002/rmv.2003.
  • 加载中
图(9) / 表(1)
计量
  • 文章访问数:  151
  • HTML全文浏览量:  46
  • PDF下载量:  18
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-06-09
  • 网络出版日期:  2021-08-18
  • 刊出日期:  2021-08-31

目录

    /

    返回文章
    返回

    在线交流

    防诈骗公告

    近期有不法分子以本刊编辑身份添加作者微信,请务必提高警惕!本刊关于稿件的一切事项通知均采用编辑部唯一邮箱(jbjc@icdc.cn)和座机(010-58900732)联系作者,且在录用稿件后仅收取版面费,无其他任何名目费用(如审稿费和加急费等),非编辑部邮箱发送的本刊收费用通知等均为诈骗,不要随意汇入款项!如有可疑及时致电编辑部核实确认!